Cefiderocol
1704R2133
Phase 2 small_molecule completed
Quick answer
Cefiderocol for Gram-negative Bacterial Infections is a Phase 2 program (small_molecule) at Shionogi B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Shionogi B.V.
- Indication
- Gram-negative Bacterial Infections
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed